Literature DB >> 17373198

Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.

Minerva Gómez1, Maira E Herz Ruelas, Oliverio Welsh, Horacio Decanini Arcaute, Jorge Ocampo-Candiani.   

Abstract

Pityriasis rubra pilaris has no single effective therapy and there are some cases resistant to multiple treatments. Psoriasis has clinical and therapeutic response overlaps with pityriasis rubra pilaris and there are several therapies common to both, such as retinoids, methotrexate, cyclosporine A, phototherapy, and most recently infliximab. We report a case of a 10-year-old boy with pityriasis rubra pilaris unresponsive to topical corticosteroids, salicylic acid, pimecrolimus, calcitriol, calcipotriol, ultraviolet B targeted phototherapy, isotretinoin, systemic PUVA, acitretin, and etanercept. He was treated with efalizumab 1 mg/kg weekly and a successful outcome was obtained with a 50% improvement after the first dose. The patient remains in remission after 9 months of treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17373198

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  [Successful therapy of discoid lupus erythematosus with efalizumab].

Authors:  N Booken; T Schumann; M Fuchslocher; S Goerdt; M Goebeler
Journal:  Hautarzt       Date:  2010-03       Impact factor: 0.751

Review 2.  The continuing evolution of targeted therapy for inflammatory skin disease.

Authors:  C Schlapbach; A A Navarini
Journal:  Semin Immunopathol       Date:  2015-09-30       Impact factor: 9.623

3.  Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl.

Authors:  Lauren Bonomo; Aishwarya Raja; Kathryn Tan; Emma Guttman-Yassky
Journal:  JAAD Case Rep       Date:  2018-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.